...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Sciences >Antiphospholipid Syndrome and HCV Infection
【24h】

Antiphospholipid Syndrome and HCV Infection

机译：抗磷脂综合征和HCV感染

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The research work was conducted to investigate the issue of anti-cardiolipin antibodies (ACAs) and HCV infection, two groups of patients had been selected; the group I (HCV group) comprised 25 patients proved to have HCV infection by PCR test and group II (thrombotic group) comprised 25 patients presented with different thrombotic events. In addition, 25 subjects were selected as a control group. For all patients, estimation of ACA-IgG was done, where 2 samples were taken and the first (initial) sample was at the start of the work. With recent thrombosis, the initial sample was withdrawn before starting heparin. The second (follow-up) sample was taken at least 2 months after the initial one. Results showed that 40% (10 / 25) of group I cases have persistently elevated ACA-IgG and further 40% of them (4 / 25) have the propensity for thrombosis, which was rather predominantly venous in nature. Fifty two percent of unexplained thrombotic cases in group II are ACA-IgG positive; thus the anti-phospholipid syndrome (APS) can account for a good percentage of unexplained thrombosis. Also, there was a significant reduction in platelet count with the rise of ACA-IgG in both groups. Therefore, the laboratory evaluation of APS is suggested to pass in two steps, catching isolated thrombocytopenia, waiting for the assessment of the ACAs as a more specific marker. Finally we can concluded that, the APS is an important additional extra-hepatic feature of HCV and should be anticipated and considered in the differential diagnosis of the different systemic features of this common hepatotropic virus. Advice to screening for the presence of APS in cases with HCV infection by ACA-IgG to be early submitted for antiviral therapy, also we suggested a further work to evaluating its probable clearance after effective successful antiviral therapy.
机译：进行了研究工作以调查抗心磷脂抗体（ACA）和HCV感染的问题，已选择了两组患者。第一组（HCV组）包括25例经PCR测试证实患有HCV感染的患者，第二组（血栓形成组）包括25例出现不同血栓事件的患者。另外，选择25名受试者作为对照组。对于所有患者，都进行了ACA-IgG的估计，其中采集了2个样本，而第一个（初始）样本是在工作开始时进行的。近期有血栓形成时，在开始肝素治疗之前先取出初始样本。第二份（随访）样本是在第一份样本之后至少两个月采集的。结果显示，I组病例中40％（10/25）的ACA-IgG持续升高，其中40％（4/25）的患者有血栓形成的倾向，而静脉血的形成主要是静脉血。 II组中52％的原因不明的血栓形成病例为ACA-IgG阳性;因此，抗磷脂综合症（APS）占无法解释的血栓形成的很大百分比。另外，两组中随着ACA-IgG的升高，血小板计数也显着降低。因此，APS的实验室评估建议分两个步骤进行，即捕获孤立的血小板减少症，等待评估ACA作为更特异性的标志物。最后，我们可以得出结论，APS是HCV的另一个重要肝外功能，应该在鉴别诊断这种普通肝炎病毒的不同全身特征时加以预期和考虑。对于早期被ACA-IgG感染HCV的丙型肝炎病毒感染病例，应筛查APS的存在的建议，我们还建议开展进一步的工作，以评估成功成功的抗病毒治疗后其清除率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号